MediMix aims to bring high value medical information to Belgian healthcare professionals via multiple channels. Our team covers congresses and symposia all over the world, particularly in the hematology domain. In collaboration with Belgian and international experts, we bring the newest data to Belgian physicians.
Dr Evren Alici, principal researcher and head of the cell and gene therapy group at the Karolinska Institute in Stockholm, Sweden was so kind to summarise data on NK cell
In this presentation, data sourced from the CIBM-TR registry were utilized to assess the differential outcomes of Brexu-cel therapy in patients with R/R MCL exhibiting high-risk features, such as delTP53/17P,
At the ASH meeting, Professor Oliva presented the patient-reported outcomes from the QuANTUM-First trial, a phase 3 clinical investigation assessing the efficacy and safety of quizartinib. Quizartinib, is approved in
Dr Cesar Rodriguez, affiliated with Mount Sinai in New York, presents a research study examining the impact of isatuximab (Isa) on the occurrence of hypogammaglobulinemia (HGG) and the concomitant risk
In this study, Dr Aaron Goldberg from the Memorial Sloan Kettering Cancer Center presents a comparative analysis of outcomes and healthcare research utilization in patients with AML treated with venetoclax
Prof George Follows, a consulting haematologist from Nuffield Health Cambridge Hospital, presents a post-hoc analysis of the ELEVATE-TN trial, a prospective, randomized study involving treatment-naïve elderly CLL patients. Patients were
In this presentation, Dory Abelman, a PhD candidate at the Princess Margaret Cancer Centre, University of Toronto, assesses the concordance of molecular profiles between cancer cells derived from bone marrow
Dr Betsy O’Donnell, a haematologist at the Dana-Farber Cancer Institute (US), presents the findings from the SKylaRK trial, a phase 2 study in NDMM patients eligible for transplantation, who received
